Immunovant plans to initiate a Phase 1 clinical trial of IMVT-1402 in early calendar year 2023, contingent on clearance of its IND application, with initial data readout from this trial expected in mid-calendar year 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMVT:
- Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
- Immunovant participates in a conference call hosted by Truist
- Wells Fargo upgrades Immunovant to Overweight, raises price target to $27
- Immunovant upgraded to Overweight from Equal Weight at Wells Fargo
- Roivant’s upcoming data readouts could move stock higher, says Cantor Fitzgerald